Hematologic Malignancy
Central Nervous System Lymphoma
CI-CAN-00000653Explore in graph →
Hematologic81 active trials
- NCIt
- C212063
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000653Explore in graph →
Clinical trials
214 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (15)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00293475 | Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 81 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT03582254 | Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years(LOCALYSE) | unknown | N/A | 62 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 10, 2021 |
| clinicaltrials |
| NCT05021770 | Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma | unknown | Phase 1 / Phase 2 | 29 | Huiqiang HuangOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT04129710 | A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) | unknown | Phase 2 | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT04938297 | Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma | unknown | Phase 2 | 100 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 24, 2021 | clinicaltrials |
| NCT04899427 | Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma | unknown | Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT04899453 | Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT03569995 | [CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma | unknown | Phase 2 | 35 | Won Seog KimOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT04457869 | A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) | unknown | Phase 2 | 43 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 0 | Oct 22, 2020 | clinicaltrials |
| NCT02657785 | Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02836158 | Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04516655 | A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients(C-R-HDMTX) | unknown | Phase 2 | 51 | Fudan UniversityOTHER | 0 | Aug 18, 2020 | clinicaltrials |
| NCT01973062 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma | terminated | Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT04120350 | R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty(REMLA) | unknown | Phase 1 / Phase 2 | 47 | Peking Union Medical College HospitalOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT00267865 | Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01251913 | A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes | terminated | — | 7 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2019 | clinicaltrials |
| NCT02652715 | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | completed | N/A | 29 | Mayo ClinicOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT04083066 | Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma | unknown | Phase 4 | 20 | Mingzhi ZhangOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT04066920 | IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL | unknown | Phase 2 | 30 | Deok-Hwan YangOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT02669511 | PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | completed | Phase 2 | 21 | PIQUR Therapeutics AGINDUSTRY | 0 | Jul 9, 2019 | clinicaltrials |
| NCT03558750 | Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma | terminated | Phase 1 | 6 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 25, 2019 | clinicaltrials |
| NCT03859544 | Molecular Prognosis of Lymphomas of the Central Nervous System (ALYCE-molecular)(ALYCEmolecular) | unknown | — | 74 | Hospices Civils de LyonOTHER | 1 | Mar 1, 2019 | clinicaltrials |
| NCT00863460 | Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients(PRECIS) | unknown | Phase 2 | 140 | Institut CurieOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT01319591 | Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate | completed | — | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT03120000 | PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | withdrawn | Phase 2 | 0 | PIQUR Therapeutics AGINDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03733327 | BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 20 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03690895 | Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy(LCPVIH) | completed | — | 51 | Fondation Ophtalmologique Adolphe de RothschildNETWORK | 1 | Oct 1, 2018 | clinicaltrials |
| NCT03212807 | Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL(DuRIANS) | withdrawn | Phase 2 | 0 | Singapore General HospitalOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT03392714 | Bendamustine-based Combination Therapy for PCNSL | unknown | Phase 2 | 15 | Chonnam National University HospitalOTHER | 1 | Jan 8, 2018 | clinicaltrials |
| NCT02301364 | Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) | completed | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT00112593 | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | completed | N/A | 5 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00710151 | Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors | terminated | — | 80 | OHSU Knight Cancer InstituteOTHER | 2 | Apr 21, 2017 | clinicaltrials |
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia(VISMOLY) | terminated | Phase 2 | 31 | The Lymphoma Academic Research OrganisationOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT00193973 | Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma | completed | Phase 2 | 20 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Feb 17, 2017 | clinicaltrials |
| NCT02113007 | Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma | terminated | Phase 2 | 2 | SCRI Development Innovations, LLCOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02983942 | Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 50 | Beijing Tiantan HospitalOTHER | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02934204 | Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma | unknown | Phase 2 | 51 | Guangdong Provincial People's HospitalOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT02779101 | Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) | unknown | Phase 2 | 21 | Prof. Dr. Matthias PreusserOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT00967200 | Study of Tissue Samples From Patients With Glioma or Other Brain Tumors | completed | — | 180 | University Hospital, MontpellierOTHER | 1 | Nov 24, 2015 | clinicaltrials |
| NCT00916630 | Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed) | completed | Phase 1 | 18 | Massachusetts General HospitalOTHER | 1 | Sep 23, 2015 | clinicaltrials |
| NCT01960192 | Treatment of Primary CNS Lymphoma(FVD) | unknown | Phase 4 | 50 | Mingzhi ZhangOTHER | 1 | Jul 21, 2015 | clinicaltrials |
| NCT02399189 | MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 2 | 39 | Jun ZhuOTHER | 1 | Apr 13, 2015 | clinicaltrials |
| NCT00221325 | A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma | completed | Phase 1 | 14 | University of California, San FranciscoOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01158274 | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 2 | Nov 7, 2014 | clinicaltrials |
| NCT01231919 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 2 | Apr 29, 2014 | clinicaltrials |
| NCT00499811 | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00293345 | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Sep 22, 2021source: clinicaltrials